Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of September 2019. The registrant is a foreign private issuer incorporated in Belgium, with its principal executive office in Mechelen. The filing serves to incorporate by reference a press release dated September 19, 2019, which is attached as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific financial data. It is a procedural filing referencing an external press release. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this document.
Material Changes
The filing text does not disclose specific material changes to financial position or operations. It solely references the issuance of a press release on September 19, 2019, without summarizing its content within the Form 6-K body.
Guidance, Outlook, and Risks
No guidance, outlook, management commentary, or specific risk factors are detailed in the text of this Form 6-K. The document states that the information in the attached press release (Exhibit 99.1) is incorporated by reference into the Company's Registration Statements on Forms F-3 and S-8.
Investor Verification Checklist
- Verify the content of the attached Exhibit 99.1 (Press Release dated September 19, 2019) to understand the material event triggering this filing.
- Confirm the registrant name is Galapagos NV, as the metadata reference to "Lakefront Biotherapeutics NV" appears to be incorrect based on the filing text.
- Review the referenced Registration Statements (Forms F-3 and S-8) for updated disclosures related to the press release.
- Note that this document contains no standalone financial metrics; investors must consult the company's most recent Form 20-F or quarterly reports for financial data.